Ossur has announced a 3% sales growth, measured in local currency, for 2012, which is in line with guidance of 2% to 3%. Sales totaled $399 million compared with $398 million in 2011.

Gross profit remains stable and totaled $248 million, or 62%, the same ratio as in 2011. Net profit increased in 2012 by 9% and amounted to $38 million compared with $35 million in 2011.

“This year has been yet another strong year in EMEA while it has been challenging in the US due to adverse market conditions. The fourth quarter was a record quarter in bionic sales and prosthetics sales in EMEA have been very strong during the year,” Jon Sigurosson, president and chief executive officer of Ossur, stated in a press release. “Despite turbulence in the reimbursement systems in the US, we experienced the acceptance of our high-end solutions. One of our most advanced bionic products, Power Knee, was accepted into the reimbursement system in the US as of Jan. 1, 2013. We are pleased to see the continued demand for high-end and quality solutions based on clinical and a health economical outcome.”

Altogether, Ossur released 29 orthotic and prosthetic products in 2012. Ossur estimates LCY organic sales growth for 2013 to be in the range of 2% to 4%.